CD274 and hepatocellular carcinoma: Even though the use of PD-L1 inhibitors on advanced HCC has been rapidly increasing, their use in liver transplant candidates is conventionally discouraged due to reports of severe allograft rejection, graft loss, and even death [67,68,69].